Expression of p53 and p21 and the clinical response for hyperthermochemoradiotherapy in patients with squamous cell carcinoma of the esophagus

Anticancer Research

Volumn 27, Issue 5 B, 2007, Pages 3501-3506

  Ishida, Mayumi ^a   Morita, Masaru ^a   Saeki, Hiroshi ^a   Ohga, Takefumi ^a   Sadanaga, Noriaki ^a   Watanabe, Masayuki ^a   Kakeji, Yoshihiro ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Esophageal cancer; Hyperthermia; p21; p53

Indexed keywords

CISPLATIN; PROTEIN P21; PROTEIN P53;

ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PREOPERATIVE CARE; REGRESSION ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35349022587     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Koshy M, Esiashvilli N, Landry JC, Thomas CR Jr and Matthews RH: Multiple management modalities in esophageal cancer: combined modality management approaches. Oncologist 9: 147-159, 2004.
2. Sutton P and Clark P: Neo-adjuvant treatment for oesophageal cancer. GI Cancer 3: 231-238, 2000.
3. Lehnert T: Multimodal therapy for squamous carcinoma of the esophagus. Br J Surg 86: 727-739, 1999.
4. Geh JI, Crellin AM and Glynne-Jones R: Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 88: 338-356, 2001.
5. Sugimachi K, Matsuda H, Ohno S, Fukuda A, Matsuoka H, Mori M and Kuwano H: Long-term effects on hyperthermia combined with chemotherapy and irradiation for the treatment of patients with carcinoma of the esophagus. Surg Gynecol Obstet 167: 319-323, 1988.
6. Kitamura K, Kuawano H, Watanabe M, Nozoe T, Yasuda M, Sumiyoshi K, Saku M and Sugimachi K: Prospective randomized study of hyperthermia combined with chemoradiotherapy for esophageal cancer. J Surg Oncol 60: 55-58, 1995.
7. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elisa D, Lozach P, Ollier JC, Pavy JJ, Mercier M and Sahmoud T: Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337: 161-167, 1997.
8. Urva SG, Orringer MB, Turrisi A, Iannettoni M, Foeastiere A and Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-313, 2001.
9. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R and Harris CC: Somatic point mutation in the p53 gene of human tumors and cell lines: update compilation. Nucleic Acid Res 24: 141-146, 1996.
10. Kern SE, Pietenpol JA, Thiagalingam S, Sevmour A, Kinzler KW and Vogelstein B: Oncogenic forms of p53-regulated gene expression. Science 256: 827-830, 1992.
11. waf1/cip1 influence the sensitivity of chemoradiation therapy for esophageal cancer. Hepatogastroenterology 45: 1497-1504, 1998.
12. Kobayashi S, Koide Y, Endo M, Isono K and Ochiai T: The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability. Am J Surg 177: 497-502, 1999.
13. Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E and Forastiere A: Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemotherapy. Clin Cancer Res 9: 6461-6468, 2003.
14. Japanese Society for Esophageal Disease. Guideline for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: Preface, general principles, part1. Esophagus 1: 61-88, 2004.
15. Japanese Society for Esophageal Disease. Guideline for clinical and pathologic studies on carcinoma of the esophagus, 9th edition: part II Esophagus 1: 107-125, 2004.
16. Yang B, Rice TW, Adelstein DJ, Rybicki LA and Goldblum JR: Overexpression of p53 protein associated response to chemoradiotherapy in patients with esophageal carcinoma. Mod Pathol 12: 251-256, 1999.
17. Samejima R, Kitajima Y, Yunotani S and Mitazaki K: Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res 19: 5515-5521, 1999.
18. Kajiyama Y, Hattori K, Tomita N, Amano T, Iwanuma Y, Narumi K, Udagawa H and Tsurumaru M: Histopathologic effects of neoadjuvant therapies for advanced squamous cell carcinoma of the esophagus: multivariate analysis of predictive factors and p53 overexpression. Dis Esophagus 15: 61-66, 2002.
19. Michel P, Magois K, Robert V, Chiron A, Lepessot F, Bodenant C, Roque I, Seng SK, Frebourg T and Paillot B: Prognostic value of Tp53 transcriptional activity on p21 and bax in patients with esophageal squamous cell carcinoma treated by definitive chemoradiontherapy. Int J Radiat Oncol Biol Phys 54: 379-385, 2002.
20. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, Tsurumaru M and Sasai K: c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 57: 1323-1327, 2003.
21. Nakamura T, Hayashi K, Ota M, Ide H, Takasaki K and Mituhashi M: Expression of p21(Waf1/Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy. Dis Esophagus 17: 315-321, 2004.
22. Derka S, Vairaktaris E, Papakosta V, Vassiliou S, Acil Y, Vylliotis A, Spyridonidou S, Lazaris AC, Mourouzis C, Kokkori A, Moulavasili P, Perea D, Donta I, Yapijakis C and Patsouris E: Cell proliferation and apoptosis culminate in early stages of oral oncogenesis. Oral Oncol 42: 540-550, 2006.
23. Ito T, Kaneko K, Makino R, Ito H, Konishi K, Kurahashi T, Kitahara T and Mitamura K: Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol 36: 303-311, 2001.
24. Ito S, Ohga T, Saeki H, Nakamura T, Watanabe M, Tanaka S, Kakeji Y and Maehara Y: p53 Mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstrate field carcinogenesis. Int J Cancer 113: 22-28, 2005.
25. Papakosta V, Vairaktaris E, Vylliotis A, Derka S, Nkenke E, Vassiliou S, Lazaris A, Mourouzis C, Rallis G, Spyridonidou S, Anagnostopoulou S, Perrea D, Donta I, Yapijakis C and Patsouris E: The co-expression of c-myc and p53 increase and reacshes a plateau early in oral oncogenesis. Anticancer Res 26: 2957-2962, 2006.
26. Sherr CJ and Robert JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999.
27. Qiu H, Sirivongs P, Rothenberger M, Rothenberger DA and Garcia-Aguilar J: Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 43: 451-459, 2000.
28. Ahrendt SA, Brown HM, Komorowski RA, Zhu YR, Wilson SD, Erickson BA, Ritch PS, Pitt HA and Demeure MJ: p21 WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic caner. Surgery 128: 520-530, 2000.
29. Nakamura M, Miyamoto S, Maeda H, Zhang SC, Sangai T, Ishii G, Hasebe T, Endoh Y, Saito N, Asaka M and Ochiai A: Low levels of insulin-like growth factor expression at cancer cell membrane predict liver metastasis in Dukes' C human colorectal cancers. Clin Cancer Res 10: 8434-8441, 2004.
30. Nakamura Y, Otani S, Otaka M, Shimata T, Takahashi S, Saito M, Takahashi T, Komatsu M, Suzuki T, Okubo S, Hayashi M and Sasano H: Gastric small cell carcinoma with marked response to neoadjuvant chemotherapy. Int J Clin Oncol 10: 348-352, 2005.
31. Nakashima S, Natsugoe S, Matsumoto M, Kijima F, Takebayashi Y, Okumura H, Shimada M, Nakano S, Kusano C, Baba M, Takao S and Aikou T: Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Res 20: 1933-1937, 2000.